학술논문
SD1000: 96.4% SVR12 in 1237 patients with hepatitis C genotypes 1, 2, 3, 4 using co-formulated sofosbuvir/daclatasvir tablets manufactured in Iran - a multicenter phase 3 clinical trial including HIV co-infected, transplant, and hemodialysis patients
Document Type
Journal
Author
Merat, S.; Poustchi, H.; Sharifi, A-H; Nateghi, A.; Hajiani, E.; Gharavi, A.; Somi, M-H; Ghadir, M-R; Kalantari, H.; Mansour-Ghanaei, F.; Karimi, J.; Fattahi, M-R; Baniasadi, N.; Moosavy, S.; Dehghan-Manshadi, S-A; Sofian, M.; Sayad, B.; Abazar, P.; Amiriani, T.; Bakhshipour, A.; Mokhtare, M.; Sharifian, A.; Minakari, M.; Zahedi, M. J.; Sohrabi, M.; Ghezloo, M.; Jamali, R.; Toosi, S. M. V.; Afshar, B.; Maleki, I.; Ziaee, M.; Hormati, A.; Samani, F. R.; Eslami, L.; Fakheri, H.; Goshayeshi, L.; Sali, S.; Sohrabpour, A. A.; Norouzi, A.; Sardarian, H.; Janbakhsh, A.; Shayesteh, A. A.; Ahmadi, L.; Merat, D.; Shayesteh, E.; Malekzadeh, R.
Source
Subject
Language
English
ISSN
13652893